Table 2C. Temporal profile of IL-6 mRNA and protein in experimental stroke.
| Ischemia model | Strain | Method | Time profile and cellular synthesis | Reference |
|---|---|---|---|---|
| Mouse | ||||
| Proximal pMCAO (filament) | C57BL/6 | RPA | Elevated IL-6 mRNA from 10 hours. Peak expression at 18 hours (4, 10, 18, and 96 hours) | Hill et al (1999) |
| Proximal tMCAO (2 hours, filament) | C57BL/6 | RPA | Elevated IL-6 mRNA from 10 hours. Peak expression at 18 hours (4, 10, 18, and 96 hours) | Hill et al (1999) |
| Rat | ||||
| Proximal tMCAO (2 hours, suture) | SD | Real-time RT-PCR | Elevated IL-6 mRNA from 3 to 72 hours. Peak expression at 6 hours (3, 6, 12, 24, and 48 hours) | Berti et al (2002) |
| PMCAO (occluded and cut) | SHR | Northern blot | Elevated IL-6 mRNA from 3 hours. Peak expression at 12 hours (1, 3, 6, 12, 24 hours, and 5 days) | Wang et al (1995) |
| Proximal pMCAO Proximal tMCAO (1.5 hours, suture) | SD SD | Bioactivity assay Western blot Immuno | Elevated IL-6 from 2 hours. Peak expression at 24 hours (2, 8, and 24 hours) Elevated at 24 hours. (24 hours) Eleveted IL-6 from 3.5 hours. Peak expression at 12 to 24 hours (3.5, 12, 24, and 48 hours) | (Loddick et al, 1998; Suzuki et al, 1999) |
IL-6, interleukin-6; immuno, immunohistochemistry; pMCAO, permanent middle cerebral artery occlusion; RPA, RNAse protection assay; RT-PCR, reverse transcription polymerase chain reaction; SD, sprague dawley; SHR, spontaneously hypertensive rats; tMCAO, transient middle cerebral artery occlusion.
Time for tMCAO is time point after reperfusion. Time in parenthesis indicate the time-points investigated in the study, except the baseline corresponding to the time ‘0', which is not indicated.